A wealth of evidence supports the notion that MCL-1 inhibitors would be efficacious for a broad range of haematological malignancies, including for aggressive MYC-driven lymphomas, such as Burkitt Lymphomas (BL), which are known to be highly dependent on MCL-1 for continued survival and proliferation [10–16]. Here, MYC is linked to Burkitt lymphoma.